R-CHOP regimen: Difference between revisions
Gerald Chi (talk | contribs) m (→Indications) |
Gerald Chi (talk | contribs) m (→Indications) |
||
| Line 20: | Line 20: | ||
==Indications== | ==Indications== | ||
* [[Diffuse large B-cell lymphoma]]<ref>{{Cite journal | doi = 10.1056/NEJMoa011795 | issn = 1533-4406 | volume = 346 | issue = 4 | pages = 235–242 | last = Coiffier | first = Bertrand | coauthors = Eric Lepage, Josette Briere, Raoul Herbrecht, Hervé Tilly, Reda Bouabdallah, Pierre Morel, Eric Van Den Neste, Gilles Salles, Philippe Gaulard, Felix Reyes, Pierre Lederlin, Christian Gisselbrecht | title = CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma | journal = The New England Journal of Medicine | date = 2002-01-24 | pmid = 11807147 }}</ref> | * [[Diffuse large B-cell lymphoma|Diffuse large B-cell lymphoma, untreated]]<ref>{{Cite journal | doi = 10.1056/NEJMoa011795 | issn = 1533-4406 | volume = 346 | issue = 4 | pages = 235–242 | last = Coiffier | first = Bertrand | coauthors = Eric Lepage, Josette Briere, Raoul Herbrecht, Hervé Tilly, Reda Bouabdallah, Pierre Morel, Eric Van Den Neste, Gilles Salles, Philippe Gaulard, Felix Reyes, Pierre Lederlin, Christian Gisselbrecht | title = CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma | journal = The New England Journal of Medicine | date = 2002-01-24 | pmid = 11807147 }}</ref> | ||
==See also== | ==See also== | ||
Revision as of 16:26, 20 February 2015
|
WikiDoc Resources for R-CHOP regimen |
|
Articles |
|---|
|
Most recent articles on R-CHOP regimen Most cited articles on R-CHOP regimen |
|
Media |
|
Powerpoint slides on R-CHOP regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on R-CHOP regimen at Clinical Trials.gov Trial results on R-CHOP regimen Clinical Trials on R-CHOP regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on R-CHOP regimen NICE Guidance on R-CHOP regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on R-CHOP regimen Discussion groups on R-CHOP regimen Patient Handouts on R-CHOP regimen Directions to Hospitals Treating R-CHOP regimen Risk calculators and risk factors for R-CHOP regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for R-CHOP regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Rituximab-Cyclophosphamide-Hydroxydaunorubicin-Oncovin-Prednisone regimen
Overview
R-CHOP regimen refers to an immunochemotherapy regimen consisting of rituximab, cyclophosphamide, hydroxydaunorubicin hydrochloride (doxorubicin hydrochloride), vincristine (Oncovin) and prednisone used to treat both indolent and aggressive forms of non-Hodgkin lymphoma.[1][2]
Regimen
H – Doxorubicin (Hydroxydaunomycin)
Indications
See also
- CEP regimen
- CHOEP regimen
- CHOP regimen
- COP regimen
- R-CHOEP regimen
- R-Maxi-CHOP regimen
- R-Mega-CHOEP regimen
References
- ↑ "NCI Thesaurus".
- ↑ "R-CHOP - National Cancer Institute".
- ↑ Coiffier, Bertrand (2002-01-24). "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma". The New England Journal of Medicine. 346 (4): 235–242. doi:10.1056/NEJMoa011795. ISSN 1533-4406. PMID 11807147. Unknown parameter
|coauthors=ignored (help)